SAN

79.89

+0.67%↑

SHL.DE

42.2

-0.12%↓

ORNBV.FI

68.5

-1.08%↓

QDEL

23.48

-2.33%↓

ACB

3.76

+5.92%↑

SAN

79.89

+0.67%↑

SHL.DE

42.2

-0.12%↓

ORNBV.FI

68.5

-1.08%↓

QDEL

23.48

-2.33%↓

ACB

3.76

+5.92%↑

SAN

79.89

+0.67%↑

SHL.DE

42.2

-0.12%↓

ORNBV.FI

68.5

-1.08%↓

QDEL

23.48

-2.33%↓

ACB

3.76

+5.92%↑

SAN

79.89

+0.67%↑

SHL.DE

42.2

-0.12%↓

ORNBV.FI

68.5

-1.08%↓

QDEL

23.48

-2.33%↓

ACB

3.76

+5.92%↑

SAN

79.89

+0.67%↑

SHL.DE

42.2

-0.12%↓

ORNBV.FI

68.5

-1.08%↓

QDEL

23.48

-2.33%↓

ACB

3.76

+5.92%↑

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

78.4 -0.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

77.95

Max

78.6

Chiffres clés

By Trading Economics

Revenu

49M

76M

Ventes

51M

210M

P/E

Moyenne du Secteur

32.405

110.024

BPA

1.135

Rendement du dividende

1.21

Marge bénéficiaire

35.965

Employés

2,197

EBITDA

49M

84M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.21%

2.26%

Prochains Résultats

25 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

693M

3.9B

Ouverture précédente

78.65

Clôture précédente

78.4

Sentiment de l'Actualité

By Acuity

24%

76%

40 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 févr. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 févr. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 févr. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 févr. 2026, 23:21 UTC

Résultats

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 févr. 2026, 23:20 UTC

Résultats

Nickel Industries 2025 Operating Profit US$126.4 Million

22 févr. 2026, 23:19 UTC

Résultats

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 févr. 2026, 23:19 UTC

Résultats

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 févr. 2026, 23:18 UTC

Résultats

Nickel Industries Won't Pay a Final Dividend

22 févr. 2026, 23:16 UTC

Résultats

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 févr. 2026, 21:35 UTC

Résultats

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 févr. 2026, 21:34 UTC

Résultats

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 févr. 2026, 21:34 UTC

Résultats

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 févr. 2026, 21:33 UTC

Résultats

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 févr. 2026, 21:33 UTC

Résultats

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 févr. 2026, 21:28 UTC

Résultats

Ampol Final Dividend A$0.60/Share

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Revenue A$31.37 Billion, Down 10%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 févr. 2026, 14:31 UTC

Acquisitions, Fusions, Rachats

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 févr. 2026, 23:12 UTC

Acquisitions, Fusions, Rachats

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 févr. 2026, 22:12 UTC

Résultats

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 févr. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 févr. 2026, 21:23 UTC

Résultats

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 févr. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 févr. 2026, 21:01 UTC

Acquisitions, Fusions, Rachats

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 févr. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

40 / 351Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat